Why Big Pharma Isn't Scared of Biosimilars

02-01-2014 Motley FoolComments (0)

BiosimilarsRemicade

The first rule of investing in pharmaceuticals is that when a drug loses patent protection, the drug maker loses sales. Remsima, a biosimilar version of Remicade, has been on sale in Korea since September 2012. Why haven't Remicade sales there fallen ...

Read more on Motley Fool

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top